147 related articles for article (PubMed ID: 9445138)
1. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components.
Kounelis S; Jones MW; Papadaki H; Bakker A; Swalsky P; Finkelstein SD
Hum Pathol; 1998 Jan; 29(1):82-7. PubMed ID: 9445138
[TBL] [Abstract][Full Text] [Related]
2. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis.
Jin Z; Ogata S; Tamura G; Katayama Y; Fukase M; Yajima M; Motoyama T
Int J Gynecol Pathol; 2003 Oct; 22(4):368-73. PubMed ID: 14501818
[TBL] [Abstract][Full Text] [Related]
3. Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.
Chen X; Arend R; Hamele-Bena D; Tergas AI; Hawver M; Tong GX; Wright TC; Wright JD
Int J Gynecol Pathol; 2017 Sep; 36(5):412-419. PubMed ID: 28700424
[TBL] [Abstract][Full Text] [Related]
4. p53 protein overexpression and gene mutation in mixed Müllerian tumors of the uterus.
Soong R; Knowles S; Hammond IG; Michael C; Iacopetta BJ
Cancer Detect Prev; 1999; 23(1):8-12. PubMed ID: 9892985
[TBL] [Abstract][Full Text] [Related]
5. p53 and K-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma, and pulmonary blastoma: implications for histogenesis.
Holst VA; Finkelstein S; Colby TV; Myers JL; Yousem SA
Am J Surg Pathol; 1997 Jul; 21(7):801-11. PubMed ID: 9236836
[TBL] [Abstract][Full Text] [Related]
6. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
7. Proliferation indices and p53-immunocytochemistry in uterine mixed mullerian tumors.
Nicòtina PA; Ferlazzo G; Vincelli AM
Histol Histopathol; 1997 Oct; 12(4):967-72. PubMed ID: 9302556
[TBL] [Abstract][Full Text] [Related]
8. p53 immunostaining suggests that uterine carcinosarcomas are monoclonal.
Mayall F; Rutty K; Campbell F; Goddard H
Histopathology; 1994 Mar; 24(3):211-4. PubMed ID: 8200622
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors.
Buza N; Tavassoli FA
Int J Gynecol Pathol; 2009 Nov; 28(6):514-21. PubMed ID: 19851197
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed müllerian tumours.
Abeln EC; Smit VT; Wessels JW; de Leeuw WJ; Cornelisse CJ; Fleuren GJ
J Pathol; 1997 Dec; 183(4):424-31. PubMed ID: 9496259
[TBL] [Abstract][Full Text] [Related]
11. Malignant mixed müllerian tumor of the uterus. Features favoring its origin from a common cell clone and an epithelial-to-mesenchymal transformation mechanism of histogenesis.
Guarino M; Giordano F; Pallotti F; Polizzotti G; Tricomi P; Cristofori E
Tumori; 1998; 84(3):391-7. PubMed ID: 9678624
[TBL] [Abstract][Full Text] [Related]
12. Role of p53 pathway alterations in uterine carcinosarcomas (malignant mixed Müllerian tumors).
Semczuk A; Ignatov A; Obrzut B; Reventos J; Rechberger T
Oncology; 2014; 87(4):193-204. PubMed ID: 25033979
[TBL] [Abstract][Full Text] [Related]
13. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics.
Kernochan LE; Garcia RL
J Natl Compr Canc Netw; 2009 May; 7(5):550-6; quiz 557. PubMed ID: 19460280
[TBL] [Abstract][Full Text] [Related]
14. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.
Wada H; Enomoto T; Fujita M; Yoshino K; Nakashima R; Kurachi H; Haba T; Wakasa K; Shroyer KR; Tsujimoto M; Hongyo T; Nomura T; Murata Y
Cancer Res; 1997 Dec; 57(23):5379-85. PubMed ID: 9393763
[TBL] [Abstract][Full Text] [Related]
15. p53 is not related to Ki-67 immunostaining in the epithelial and mesenchymal components of female genital tract carcinosarcomas.
Bałon B; Kaznowska E; Ignatov A; Steć A; Semczuk-Sikora A; Schneider-Stock R; Jóźwik M; Sulkowski S; Cybulski M; Szumiło J; Semczuk A
Oncol Rep; 2013 Oct; 30(4):1661-8. PubMed ID: 23846734
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
Pinto A; Mackrides N; Nadji M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):393-397. PubMed ID: 27801734
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed müllerian tumors). Clinicopathologic study of 82 cases.
Costa MJ; Walls J
Cancer; 1996 Feb; 77(3):533-42. PubMed ID: 8630962
[TBL] [Abstract][Full Text] [Related]
18. Malignant mullerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases.
Gallardo A; Matias-Guiu X; Lagarda H; Catasus L; Bussaglia E; Gras E; Suarez D; Prat J
Int J Gynecol Pathol; 2002 Jul; 21(3):268-72. PubMed ID: 12068173
[TBL] [Abstract][Full Text] [Related]
19. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed müllerian tumors): a clinicopathologic study of 74 cases.
Costa MJ; Vogelsan J; Young LJ
Mod Pathol; 1994 Aug; 7(6):619-27. PubMed ID: 7991520
[TBL] [Abstract][Full Text] [Related]
20. Pathology of mixed Müllerian tumours.
D'Angelo E; Prat J
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):705-18. PubMed ID: 21742560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
